(Q37133396)

18 August 2017

1 reference

title

Direct versus indirect comparisons: a summary of the evidence (English)

1 reference

18 August 2017

1

1 reference

18 August 2017

Charity G Moore

2

0 references

publication date

1 January 2008

1 reference

International Journal of Technology Assessment in Health Care

18 August 2017

published in

1 reference

18 August 2017

volume

24

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

170-177

1 reference

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Indirect comparisons: the mesh and mess of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Claims of equivalence in medical research: are they supported by the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Indirect comparisons of competing interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

Network meta-analysis for indirect treatment comparisons

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

Lessons from and cautions about noninferiority and equivalence randomized trials

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0266462308080240

7 January 2021

10.1017/S0266462308080240

Identifiers

DOI

1 reference

18 August 2017

1 reference